News
- Author:
- Neil Osterweil
Publish date: September 21, 2017
MADRID – PFS was 4.07 months for patients with advanced urothelial carcinoma randomized to ramucirumab and docetaxel, compared with 2.76 months for...
News
- Author:
- Neil Osterweil
Publish date: September 19, 2017
MADRID – The study was stopped for efficacy at the interim analysis and median PFS for abemaciclib plus letrozole or anastrozole has not yet been r...
News
- Author:
- Neil Osterweil
Publish date: September 15, 2017
MADRID – The overall response rate was 50% for 166 patients assigned to letrozole plus taselisib, compared with 39.3% for 168 patients assigned to ...
News
- Author:
- Neil Osterweil
Publish date: September 12, 2017
MADRID – The relapse-free survival curves separated early in the study, and at 1 year the rate of RFS was 88% among patients treated with the combi...
News
- Author:
- Neil Osterweil
Publish date: September 11, 2017
The rates of relapse-free survival were 71% at 12 months for patients assigned to adjuvant nivolumab, compared with 61% for adjuvant ipilimumab.
News
- Author:
- Neil Osterweil
Publish date: September 11, 2017
More answers are needed about the final number of patients who are able to crossover to osimertinib, and about the mechanism and management of osim...
News
- Author:
- Neil Osterweil
Publish date: September 10, 2017
News
- Author:
- Neil Osterweil
Publish date: August 16, 2017
Study suggests an effective way to get around the limitations of adoptive VST transfer.
News
- Author:
- Neil Osterweil
Publish date: August 15, 2017
Vitamin D deficiency was associated with greater risk of relapse and lower survival for patients with myeloid malignancies.
News
- Author:
- Neil Osterweil
Publish date: August 15, 2017
“The use of lenalidomide maintenance for transplantation-eligible patients can be considered a standard of care.”
News
- Author:
- Neil Osterweil
Publish date: August 14, 2017
Fewer than half of older adults with AML were enrolled in hospice,
News
- Author:
- Neil Osterweil
Publish date: July 26, 2017
Two studies report on the STAMPEDE and LATITUDE trials that added abiraterone acetate to androgen deprivation therapy for the treatment of metastat...
News
- Author:
- Neil Osterweil
Publish date: July 25, 2017
MADRID – Adding the proteasome inhibitor carfilzomib to induction regimens delivered quicker and deeper remissions.
News
- Author:
- Neil Osterweil
Publish date: July 20, 2017
LUGANO, SWITZERLAND – Keynote 170 investigators are enrolling adults with relapsed/refractory PMBCL who are either ineligible for ASCT following at...
News
- Author:
- Neil Osterweil
Publish date: July 20, 2017
LUGANO, SWITZERLAND – The immune checkpoint inhibitor avelumab showed efficacy against classical Hodgkin lymphoma among patients with disease progr...
